Letter to the Editor

Response to the Letter to the Editor: Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients With Systemic Sclerosis

Volume 35 · Issue 3 Publish Date: September 30, 2020
Full Text PDF HTML
DOI
Christine MARCH ORCID
Department of Rheumatology and Clinical Immunology, Charité-Universitatsmedizin Berlin, Berlin, Germany image/svg+xml
Dörte HUSCHER ORCID
Department of Rheumatology, Deutsches Rheumaforschungszentrum, Berlin, Germany image/svg+xml
Emelina PREIS ORCID
Department of Rheumatology and Clinical Immunology, Charité-Universitatsmedizin Berlin, Berlin, Germany image/svg+xml
Alexander MAKOWKA ORCID
Department of Rheumatology and Clinical Immunology, Charité-Universitatsmedizin Berlin, Berlin, Germany image/svg+xml
Jakob HOEPPNER ORCID
Department of Rheumatology and Clinical Immunology, Charité-Universitatsmedizin Berlin, Berlin, Germany image/svg+xml
Frank BUTTGEREIT ORCID
Department of Rheumatology and Clinical Immunology, Charité-Universitatsmedizin Berlin, Berlin, Germany image/svg+xml
Gabriela RIEMEKASTEN ORCID
Department of Rheumatology, Universitätsklinikum Schleswig Holstein, Campus Lübeck, Lübeck, Germany image/svg+xml
Kristina NORMAN ORCID
Charité-Universitatsmedizin Berlin, Research Group on Geriatrics, Berlin, Germany image/svg+xml
Elise SIEGERT ORCID
Department of Rheumatology and Clinical Immunology, Charité-Universitatsmedizin Berlin, Berlin, Germany image/svg+xml
Christine MARCH, Dörte HUSCHER, Emelina PREIS, Alexander MAKOWKA, Jakob HOEPPNER, Frank BUTTGEREIT, … Elise SIEGERT. (2020). Response to the Letter to the Editor: Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients With Systemic Sclerosis. Archives of Rheumatology, 35(3), 460–461. https://doi.org/10.46497/ArchRheumatol.2020.00720
Full Text PDF HTML

Abstract

Thank you very much for your interest in our article “Prevalence of Depressive Symptoms in Patients with Systemic Sclerosis”. We value your contribution to central questions on prevalence and relevance of depressive disorders in this field and are glad to respond to your concerns.

We are fully aware that the Major Depression Inventory (MDI) does not allow us to diagnose depressive disorders or to estimate its prevalence among patients with systemic sclerosis (SSc). At no point in our study did we claim that we assessed the prevalence of depression in SSc.[1]

You might be right that the scientific value of estimating the prevalence of MDI-relevant items is limited. However, as we mention in the discussion of our paper, we want to raise the awareness for mental health issues in SSc without providing psychiatric diagnoses, measuring significant impairment or estimating the prevalence of depressive disorders in SSc. Also, we did not evaluate the MDI as a screening tool for depressive disorders in SSc. Our primary interest was to assess the number of patients suffering from depressive symptoms and who might thus benefit from systematic evaluation of mental health issues.

We share your concerns regarding the overestimation of depressive disorders by depression symptom questionnaires. However, we chose the MDI because it is known to be a rather conservative measure for depressive symptoms according to comparative studies using other self-report questionnaires.[2] At the same time, it is short enough to be handed out to patients in an out-patient setting. Hence, it might potentially serve as a screening tool; to evaluate this was not the aim of your study.

Of note, as mentioned in our paper, we were able to confirm a lower prevalence of these symptoms than stated in other studies.[3-9] This is in line with previous findings from Nielsen et al.[2] indicating that the MDI is a more conservative tool and which may support the idea that the MDI should be evaluated as a screening tool for depressive disorders in SSc.

Similar Articles

Article Info
Published In
Journal Archives of Rheumatology
Volume / Issue Volume 35 · Issue 3
Pages 460-461
History
Published Online September 30, 2020
License
Affiliations
Christine MARCH ORCID
Department of Rheumatology and Clinical Immunology, Charité-Universitatsmedizin Berlin, Berlin, Germany
Dörte HUSCHER ORCID
Department of Rheumatology, Deutsches Rheumaforschungszentrum, Berlin, Germany
Emelina PREIS ORCID
Department of Rheumatology and Clinical Immunology, Charité-Universitatsmedizin Berlin, Berlin, Germany
Alexander MAKOWKA ORCID
Department of Rheumatology and Clinical Immunology, Charité-Universitatsmedizin Berlin, Berlin, Germany
Jakob HOEPPNER ORCID
Department of Rheumatology and Clinical Immunology, Charité-Universitatsmedizin Berlin, Berlin, Germany
Frank BUTTGEREIT ORCID
Department of Rheumatology and Clinical Immunology, Charité-Universitatsmedizin Berlin, Berlin, Germany
Gabriela RIEMEKASTEN ORCID
Department of Rheumatology, Universitätsklinikum Schleswig Holstein, Campus Lübeck, Lübeck, Germany
Kristina NORMAN ORCID
Charité-Universitatsmedizin Berlin, Research Group on Geriatrics, Berlin, Germany
Elise SIEGERT ORCID
Department of Rheumatology and Clinical Immunology, Charité-Universitatsmedizin Berlin, Berlin, Germany
Cite this Article
Christine MARCH, Dörte HUSCHER, Emelina PREIS, Alexander MAKOWKA, Jakob HOEPPNER, Frank BUTTGEREIT, … Elise SIEGERT. (2020). Response to the Letter to the Editor: Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients With Systemic Sclerosis. Archives of Rheumatology, 35(3), 460–461. https://doi.org/10.46497/ArchRheumatol.2020.00720
Share
Outlines